- Home
- IPHA vs SCPH Comparison
IPHA vs SCPH Comparison
Compare IPHA & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- SCPH
- Stock Information
- Founded
- IPHA 1999
- SCPH 2013
- Country
- IPHA France
- SCPH United States
- Employees
- IPHA N/A
- SCPH N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- IPHA Health Care
- SCPH Health Care
- Exchange
- IPHA Nasdaq
- SCPH Nasdaq
- Market Cap
- IPHA 191.0M
- SCPH 163.3M
- IPO Year
- IPHA 2019
- SCPH 2017
- Fundamental
- Price
- IPHA $2.28
- SCPH $5.40
- Analyst Decision
- IPHA Strong Buy
- SCPH Strong Buy
- Analyst Count
- IPHA 1
- SCPH 2
- Target Price
- IPHA $11.50
- SCPH $19.00
- AVG Volume (30 Days)
- IPHA 6.3K
- SCPH 263.3K
- Earning Date
- IPHA 09-12-2024
- SCPH 11-06-2024
- Dividend Yield
- IPHA N/A
- SCPH N/A
- EPS Growth
- IPHA N/A
- SCPH N/A
- EPS
- IPHA N/A
- SCPH N/A
- Revenue
- IPHA $36,202,722.00
- SCPH $24,048,000.00
- Revenue This Year
- IPHA N/A
- SCPH $195.62
- Revenue Next Year
- IPHA $105.84
- SCPH $145.07
- P/E Ratio
- IPHA N/A
- SCPH N/A
- Revenue Growth
- IPHA N/A
- SCPH 549.77
- 52 Week Low
- IPHA $1.81
- SCPH $3.24
- 52 Week High
- IPHA $3.15
- SCPH $7.55
- Technical
- Relative Strength Index (RSI)
- IPHA 50.55
- SCPH 60.05
- Support Level
- IPHA $2.27
- SCPH $4.97
- Resistance Level
- IPHA $2.41
- SCPH $5.40
- Average True Range (ATR)
- IPHA 0.11
- SCPH 0.23
- MACD
- IPHA -0.00
- SCPH 0.00
- Stochastic Oscillator
- IPHA 52.94
- SCPH 91.38
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.